Statin-induced rhabdomyolysis: a complication of a commonly overlooked drug interaction
Author(s) -
Saad Ezad,
Hooria Cheema,
Nicholas Collins
Publication year - 2018
Publication title -
oxford medical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.169
H-Index - 9
ISSN - 2053-8855
DOI - 10.1093/omcr/omx104
Subject(s) - rhabdomyolysis , medicine , simvastatin , statin , clarithromycin , drug , cyp3a4 , drug interaction , intensive care medicine , complication , myalgia , myopathy , pharmacology , cytochrome p450 , metabolism , helicobacter pylori
Rhabdomyolysis is a well-documented side effect of statin therapy. This risk is increased with concurrent use of medications that inhibit cytochrome p450-3A4 (CYP3A4), such as macrolide antibiotics. We present the case of a 67-year-old patient who was commenced on clarithromycin on a background of simvastatin therapy, resulting in rhabdomyolysis. This case highlights the need for awareness of common drug interactions associated with statins. It also emphasizes the significance of commencing statins at a lower dose in new patients, and lastly, the importance of early recognition and management of rhabdomyolysis to prevent the development of complications.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom